Industry's View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and Commercialization
Authors:
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 107 (1) , 34-41
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Dissolution Testing for Generic Drugs: An FDA PerspectiveThe AAPS Journal, 2011
- The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation DevelopmentJournal of Pharmaceutical Sciences, 2010
- A biorelevant dissolution stress test device – background and experiencesExpert Opinion on Drug Delivery, 2010
- Biorelevant Dissolution Methods and Their Applications in In Vitro- In Vivo Correlations for Oral Formulations~!2009-09-14~!2009-11-02~!2010-04-29~!The Open Drug Delivery Journal, 2010
- Novel Application of MRI Technique Combined with Flow-Through Cell Dissolution Apparatus as Supportive Discriminatory Test for Evaluation of Controlled Release FormulationsAAPS PharmSciTech, 2010
- Investigation of dissolution behavior of diclofenac sodium extended release formulations under standard and biorelevant test conditionsDrug Development and Industrial Pharmacy, 2009
- Toward anIn VivoDissolution Methodology: A Comparison of Phosphate and Bicarbonate BuffersMolecular Pharmaceutics, 2009
- Clinical Relevance of Dissolution Testing in Quality by DesignThe AAPS Journal, 2008
- Biopharmaceutical challenges associated with drugs with low aqueous solubility—The potential impact of lipid-based formulationsAdvanced Drug Delivery Reviews, 2008
- Improving drug solubility for oral delivery using solid dispersionsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000